Hidradenitis Suppurativa Whole Blood

Hidradenitis Suppurativa Whole Blood for Inflammatory Skin Disease Research

Hidradenitis Suppurativa (HS) Whole Blood is collected from IRB-consented donors with a physician-confirmed HS diagnosis and shipped same-day for dermatology, innate immunity and inflammation research. HS is a chronic, immune-mediated inflammatory skin disease of follicular occlusion — it is not an autoantibody-driven autoimmune condition. Custom anticoagulants and collection tubes are available, and matched serum, plasma and PBMC from the same donors can be requested.

Why Whole Blood for Hidradenitis Suppurativa

HS begins with occlusion and rupture of the terminal hair follicle in apocrine-gland-bearing intertriginous skin, releasing keratin and microbial material into the dermis and triggering a strongly innate, neutrophil-rich inflammatory response that organises into nodules, abscesses and epithelialised tunnels. That biology makes granulocytes central — and granulocytes are exactly what density-gradient PBMC preparations discard.

  • Preserves neutrophils and monocytes in native proportions — critical for a disease whose lesions are dominated by neutrophilic infiltrate and tunnel formation, and for deriving neutrophil-to-lymphocyte ratio alongside the same draw.
  • Total-leukocyte RNA including granulocytes — whole-blood transcriptomics captures the granulocyte compartment that PBMC RNA-seq systematically misses, supporting work on the TNF, IL-1 and IL-17 pathways implicated in HS.
  • Ex vivo whole-blood stimulation — LPS or lesional-flora stimulation in autologous plasma keeps innate cells in a physiologic milieu, useful for studying the exaggerated innate response reported in HS.
  • Supports biologic mechanism-of-action work — HS is treated with TNF blockade and IL-17 pathway inhibition, so whole blood allows pathway readouts to be paired with documented treatment status.
  • Genomic and pharmacogenomic DNA — sufficient high-molecular-weight DNA for genotyping studies of familial and syndromic HS.
  • Paired plasma from the same tube — systemic inflammatory markers such as CRP can be measured alongside cellular readouts without a second donor visit.

Donor Stratification Available

  • Hurley stage I, II or III, and IHS4 lesion counts where recorded
  • Lesion phenotype: inflammatory nodules and abscesses versus established draining tunnels; anatomical distribution
  • Treatment status: treatment-naive, topical or systemic antibiotics, TNF inhibitor, IL-17 pathway inhibitor, or post-surgical
  • Smoking status and BMI category — both strongly associated with HS severity
  • Comorbidities including inflammatory arthritis, acne, pilonidal disease and inflammatory bowel disease
  • Matched healthy controls available, age- and sex-matched on request

Product Features

  • Fresh whole blood from clinically diagnosed hidradenitis suppurativa donors
  • Custom anticoagulants and collection tubes available (EDTA, sodium heparin, ACD, PAXgene and others on request)
  • Same-day collection and shipment
  • Custom draw volumes; values reported per lot
  • Research Use Only (RUO)

De-identified Donor Data

  • Physician-confirmed diagnosis, including Hurley stage where available
  • Demographics: age, sex assigned at birth, race/ethnicity
  • Relevant medical, medication and treatment history
  • Additional HS-specific metadata available on request

Applications

  • Whole-blood transcriptomic profiling of the granulocyte and monocyte compartments
  • Neutrophil function, chemotaxis and extracellular trap studies
  • TNF, IL-1 and IL-17 pathway biomarker discovery
  • Ex vivo stimulation and cytokine release assays in autologous plasma
  • Biologic response and non-response research stratified by treatment history
  • Systemic inflammatory burden and comorbidity research
  • DNA extraction for genotyping and pharmacogenomics
  • Assay development and qualification for dermatology clinical programmes

Other Hidradenitis Suppurativa Specimen Types

Compliance and Quality Assurance

  • IRB-approved protocols and electronic informed consent
  • HIPAA-compliant donor data handling
  • Documentation support available for regulatory review

Ordering & Customization

Hidradenitis suppurativa whole blood is available in standard and custom volumes. For pricing, availability or a specific stratification request, email learnmore@sanguinebio.com; please also contact us for international orders or documentation requirements. To browse availability across all disease states, visit our human whole blood page.

Whole Blood

Frequently Asked Questions

Showing 1–12 of 26 results

Are samples IRB approved?

1 Answer

YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.

YES – all our products are research use only (RUO).

Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.

Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.

Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.

Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.

YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.

Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.

YES – Unique donors can be specified and guaranteed based on your requirements.

For information about sample quality, please see: Quality and Compliance

YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.

1
×

Ask a Question

Need a custom Whole Blood cohort?

Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.

More Information